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Dr Soon J. Park (Rochester, Minn). Dr Kirklin and his col-
leagues are to be congratulated for this timely and important pre-
sentation. They report that a significant fraction of DT patients are
achieving a survival that is comparable with that of those who un-
dergo heart transplantation. Such finding is especially astonishing
in that these patients, by definition, were those deemed inappropri-
ate to allocate donor hearts for the concern of poor posttransplant
outcome.
Perhaps it is helpful to revisit the medical ethics governing
heart transplantation, which was established well before the cur-
rent development in LVAD therapy. Heart transplantation has
been the only therapeutic option capable of prolonging life in
these patients with end-stage heart failure. Although it is highly
effective on an individual level, its epidemiologic impact has
been trivial for there exists a significant mismatch between donors
and recipients. The donor heart remains a precious and scarce re-
source for society. Therefore, the practice of heart transplantation
has been guided by principles of justice, utility, and transplant
benefit to maximize the number of years gained by the
transplantation.
With the recent development in LVAD therapy, heart transplant
no longer seems to be the only viable option. Now, LVAD therapy
can be rendered immediately and abundantly, and it is going to
change the natural history of patients with end-stage heart failure
dramatically, whether transplant eligible or not.
As we have just been informed by Dr Kirklin, a significant frac-
tion of patients who were destined to die because heart transplant
was not an option, a typical scenario of despair that affects the vast
majority of patients, are now able to enjoy life on LVAD support.
In regard to the transplant-eligible patients, many medical cen-
ters seem to witness a significantly enhanced rate of survival in
these bridge-to-transplant patients compared with DT patients.
What is the INTERMACS bridge-to-transplant experience? How
does it compare with the attrition rate of 4% due to various causes
such as rejection, infection, allograft vasculopathy, and malig-
nancy after transplantation? What would be the appropriate
LVAD strategy in terms of patient selection, duration of support,
and timing of triggering transplantation in accordance with the
principles of transplantation? Finally, would it ever make sense
to consider LVAD as the primary therapy and reserve heart trans-
plantation as a secondary therapy?
I would welcome Dr Kirklin’s insight into some of these ques-
tions, and, once again, congratulations for ushering in a truly excit-
ing period of LVAD therapy.
Dr Kirklin. Thank you, Dr Park. Those are interesting
questions.rdiovascular Surgery c Volume 144, Number 3 597
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transplantation versus ventricular support. In the INTERMACS
database, recall that the continuous flow technology is really
now only exceeding 2 years, and during that time in the low-risk
group, the mortality rate is about 10% per year, which compares
with about 6% per year in the constant phase after cardiac trans-
plantation. Thus it is not quite there yet, even though there are spe-
cific risk factor groups that are competitive out to 2 years. Of
course, the mechanical support group includes older patients; the
median age in the INTERMACS DT group was 67 years versus
55 years in the transplant group.
Regarding the issue of using LVAD therapy as primary therapy
and transplantation secondary, of course, the goal in the future will
be to have an array of therapies that maximizes long-term survival
for patients. Whether that means initial VAD therapy followed by
transplant or initial transplant followed by a total artificial heart
will depend on the kinds of rigorous analyses that we will need
to do in the future. There is going to be the requirement for rigor-
ous transplant databases to get risk-appropriate patients as well as
ongoing analyses of these mechanical support databases.
Dr John V. Conte (Baltimore, Md). Dr Kirklin, congratulations
on a very thought-provoking paper. Having heard you say about 2
years ago that mechanical support would not be equivalent of heart
transplantation at this point in time, it is refreshing to hear that you
have somewhat changed your tone based on these data. Are you
ready right now to refer this subset of patients for mechanical sup-
port rather than transplantation? If not, what duration of long-term
follow-up would you consider necessary before you would refer
that subset of patients you just presented?
Finally, is there a financial consideration in referring this sub-
group of patients for long-term therapy?What role do the econom-
ics of transplantation andmechanical support play in this decision?
Dr Kirklin. The actual identification of patients on the trans-
plant list who could be triaged to mechanical support will depend,
of course, on their comorbidities, and there are analyses available
from previous experiences that would allow us to begin that triage
effort. Currently, however, it is going to be challenging, because
there is more contemporary data about risk stratification in
MCS patients, ironically, than there is in the current era of cardiac
transplantation. It is appropriate to begin triaging certain pa-
tients—those with multiple comorbidities who are likely to have
a long wait for cardiac transplantation, such as sensitized patients.598 The Journal of Thoracic and Cardiovascular SurgThe financial implications are complicated and will have to be
determined by societal as well as medical priorities. Clearly, we
are going to be looking at the financial implications over decades
of patient care if we are going to be using a combination of me-
chanical support, transplantation, and potentially other therapies.
Dr Conte. To answer the question directly, are you ready as you
stand there today to refer that subgroup of patients for DT as op-
posed to transplantation? I am going to hang you on your words.
Dr Kirklin. Yes.
DrR. Duane Davis (Durham, NC).Congratulations. I just want
to be a little bit cautious when you use that 20% 2-year survival in
heart transplant as your benchmark and then compare a 40-year-
old who has never had surgery getting a VAD and saying it is
equivalent. If you did a 40-year-old who never had previous car-
diac surgery, the 2-year mortality would not be 20% after a heart
transplant. It is clear that continuous VAD is getting into the ball-
park, but I am not sure I am ready to agree that it is equivalent.
Finally, when are we going to be ready to randomize between
those 2 therapies?
Dr Kirklin. The challenge in transplantation is to begin to set
some benchmark about which we could begin to have this discus-
sion, and I think a benchmark of 20% mortality at 2 years is cer-
tainly reasonable. Remember that the low-risk, 40-year-old
patient undergoing cardiac transplantation without important other
comorbidities is not the patient one would want to triage to me-
chanical support. The reason this benchmark is important is to be-
gin the discussion of those kinds of patients who could potentially
be triaged if they are a low enough risk with device therapy. How-
ever, it will only be those patients who are on the transplant list
with multiple adverse comorbidities that we are going to initially
select for triage. It will not be the otherwise healthy 40-year-old
man with a good long-term expectation from cardiac
transplantation.
Dr Joseph Amato (Chicago, Ill). Dr Kirklin, Dr Pagani, I con-
gratulate you on your work. Last week, I was at the FDA meeting
in regard to the INTERMACS pump. I witnessed the pump in ac-
tion, and all the other committee members there approved this dy-
namic pump. I disagree with the comments made in regard to the
continued improvement in searching for a bridge to transplant and
that the impact as mentioned is trivial. The experience in Europe
has been highly successful and we await a smaller version. It is
a compact and beautiful little pump.ery c September 2012
